Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02889224
Other study ID # CHUBX 2010/34
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2012
Est. completion date September 2013

Study information

Verified date October 2018
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Working hypothesis: the interactions between the endogenous endocannabinoïds (ECS) - and cortisol, the end product of the Hypothalamo-Pituitary-Adrenal (HPA) axis may play a role in the pathophysiology of Cushing's syndrome.

The investigators speculate that:

- acute or chronic variations in plasma cortisol may induce changes in the activity of the ECS

- that there is a circadian rhythm of the ECS driven by the rythm of plasma cortisol


Description:

The study aim to identify the relationship between the ECS and the HPA axis in humans with a main objective to assess if Cushing's syndrome induces changes in the ECS activity.

For this purpose:

1. the investigors will compare plasma levels of ECS between obese controls and patients with Cushing's syndrome

2. the investigors will compare plasma levels of ECS in patients with Cushing's syndrome before and immediately after curative surgery

3. the investigors will compare plasma levels of ECS in patients with hypoadrenalism before and after the intake of substitutive doses of hydrocortisone

4. the investigors will evaluate the plasma levels of ECS during a short synacthen test in healthy subjects.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

For all patients groups:

- Age = 18,

- Social security.

" Hypercortisolism " group:

- 18 < BMI < 40 kg/m2,

- Cushing's syndrome in front of :

- impaired 1 mg dexamethasone test (08:00 A.M. cortisol > 50 nmol/L)

- qualitative and quantitative disrupted circadian rhythm of cortisol with increased plasma concentrations

- free urinary cortisol upper normal range (90 µg/24H),

- Hypercortisolism that can be treated with surgery (adrenal adenoma treated with adrenalectomy or Cushing disease treated with pituitary surgery).

" Obese " group:

- Obese patients: 30 < BMI < 40 kg/m2,

- Normal HPA axis function:

- 08:00 A.M. cortisol > 250 nmol/L and peak above 550 nmol/L after 1 mg SST,

- Normal 24H free urinary cortisol and dexamethasone test. " Control " group:

- Lean or overweight patients (18 < BMI < 30 kg/m2),

- Non cortisol secreting pituitary or adrenal tumor,

- Patient in whom a biological evaluation of the HPA axis is recommended.

" Hydrocortisone " group:

- Lean or overweight patients (18 < BMI < 30 kg/m2),

- Primary or secondary adrenal insufficiency,

- With a need for hydrocortisone supplementation.

Exclusion Criteria:

- Patients with eating disorders, major depressive disorders or psychiatric disorders other than Cushing's syndrome,

- Cannabis consumption, alcoholism or drug addiction,

- Active smoking,

- cortisone treatment other than hydrocortisone,

- Pregnancy or feeding,

- Surgery for obesity,

- Incapability,

- Pathology that is life-threatening in the short term,

- Any situation that interfere with study or is risked for patient.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Obese

Procedure:
Hypercortisolism

Other:
Hydrocortisone

Control


Locations

Country Name City State
France Service d'Endocrinologie, Hopital Haut-Leveque Pessac

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fluctuations of 2-AG (2-arachidonoyl-Glycérol) plasma concentration in relationship to cortisol plasma concentration in obese arm compare to hypercortisolism arm. The primary outcome will be assessed by a measurement of plasma concentration of 2-AG during the circadian rhythm of ACTH/cortisol. Baseline
Secondary Measurement of plasma concentration of AEA (Anandamide), OEA (Oleoyl-EthanolAmide) and PEA (Palmitoyl-EthanolAmide) endocannabinoïds associated with variations of plasma cortisol in hypercortisolism arm The secondary outcome wille be assessed by a measurement of plasma concentration of AEA, OEA and PEA during the circadian rhythm of ACTH/cortisol. Baseline and day 6
Secondary Measurement of plasma concentration of AEA (Anandamide), OEA (Oleoyl-EthanolAmide) and PEA (Palmitoyl-EthanolAmide) endocannabinoïds associated with variations of plasma cortisol in hydrocortisone arm Measurement of plasma concentration of AEA, OEA and PEA on 07:30 A.M. ± 1 hour (fasting), 08:00 A.M. ± 1 hour (fasting), 09:00 A.M. ± 1 hour, 10:00 A.M. ± 1 hour, 04:00 P.M. ± 1 hour Baseline
Secondary Measurement of plasma concentration of AEA (Anandamide), OEA (Oleoyl-EthanolAmide) and PEA (Palmitoyl-EthanolAmide) endocannabinoïds in control arm who have no cortisol production problem. Measurement of plasma concentration of AEA, OEA and PEA during the circadian rhythm of ACTH/cortisol Baseline
See also
  Status Clinical Trial Phase
Completed NCT02468193 - Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Phase 2
Recruiting NCT00457587 - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Completed NCT00006278 - Study of Cushing's Syndrome Not Related to ACTH Production N/A
Completed NCT00361777 - Diagnostic Performance of Screening Tests for Cushing s Syndrome
Active, not recruiting NCT03606408 - Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 Phase 2
Completed NCT02663609 - Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
Recruiting NCT01504555 - Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Phase 3
Active, not recruiting NCT00004343 - Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome N/A
Completed NCT02922257 - Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
Completed NCT01371565 - Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Phase 3
Terminated NCT00422201 - Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Phase 2
Completed NCT00001180 - Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency N/A
Completed NCT02804750 - Study to Evaluate CORT125134 in Participants With Cushing's Syndrome Phase 2
Completed NCT00936741 - An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Phase 3
Recruiting NCT00004334 - Study of Depression, Peptides, and Steroids in Cushing's Syndrome N/A
Completed NCT03817840 - Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
Completed NCT01959711 - Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Phase 4
Completed NCT05633953 - Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
Terminated NCT00796783 - A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia N/A
Recruiting NCT02019706 - Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome Phase 2